Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus
OBJECTIVE: To evaluate the efficacy of long-term thalidomide treatment in cutaneous lesions of systemic lupus erythematosus (SLE), not responsive to conventional therapy. PATIENTS AND METHODS: Were selected 18 SLE patients (ACR criteria) with active cutaneous lesions not responsive to chloroquine, photoprotectors and low doses prednisone and who presented good response to thalidomide but relapsed after withdrawal of the drug. All female patients had no risk of pregnancy. Thalidomide was reintroduced and maintained at low dose (25-100mg/day) for a minimum of 6 months. RESULTS: Eighteen patients (16 females) with mean age of 34.2yo (16-57y.o.) received thalidomide for 6-21 months (mean 8.5m). The mean dose of prednisone at beginning of study was 38.3 mg/d and at the end was 9.7mg/d (p<0.05). Complete remission of cutaneous lesions was observed in thirteen patients (72%) and partial remission in five (28%). Side effects observed were: drowsiness in eight patients, intestinal constipation in 5, transient oliguria in 1, paresthesia of hand with normal electromyography in another one. All side effects disappeared with reduction of thalidomide dose and no patient needed to stop treatment owing to side effect. CONCLUSION: Thalidomide is a good alternative therapy to SLE patients with refractory cutaneous lesions and without any risk of pregnancy.
Main Authors: | Sato,E. I., Assis,L. S. S., Lourenzi,V. P., Andrade,L. E. C. |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Médica Brasileira
1998
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42301998000400007 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus
by: Penha,Mariana Álvares, et al.
Published: (2018) -
Refractory subacute cutaneous lupus
by: Parrey,Ashaq Hussain, et al.
Published: (2022) -
Capecitabine-induced Subacute Cutaneous Lupus Erythematosus
by: Rocha,Aroni, et al.
Published: (2019) -
Coexistence of chronic cutaneous lupus erythematosus and frontal fibrosing alopecia
by: Nascimento,Luciana Lima do, et al.
Published: (2018) -
Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects
by: Moura Filho,Jucelio Pereira, et al.
Published: (2014)